SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
PR Newswire•04/08/2026•06:15 ET
0
Whiz Insights
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies PR Newswire
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
Get started
Create a free account to read the full story.